PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12652798

[Platelet disorders].

Tsukasa Ohmori·Yutaka Yatomi
View original source ↗Export metadata ↓

Abstract

Platelets play important roles in thrombosis and hemostasis, and their abnormalities lead to hemostatic disorders or thrombotic diseases. Due to genetic technique development, the study of genetic factors related to the hereditary platelet dysfunction, and the evaluation of gene polymorphisms have been reported recently. In this article, we will focus mainly on hereditary platelet disorders and genetic variations of platelet glycoproteins involved in the pathogenesis of thrombotic diseases.

Explore related subjects

Blood Platelet DisordersGenetic VariationHumansPlatelet Membrane GlycoproteinsPolymorphism, GeneticEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Tsukasa Ohmori, Yutaka Yatomi. 2002. [Platelet disorders].. https://pubmed.ncbi.nlm.nih.gov/12652798/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Platelet dosing.

Many patients with thrombocytopenia require transfusion of platelet concentrates, and numerous factors may influence the observed response to transfusion. One factor gaining growing recognition in recent years is the consideration of the dose of platelets to administer. Review of the available data regarding the effect of platelet dose on transfusion outcome is presented in this summary, with attention to those situations that seem to require higher platelet doses. Appropriate dosing may not only improve the immediate response to transfusion, but also lead to a decrease in further platelet transfusion requirements. Recommendations supported by actual clinical data are outlined, but controlled studies are needed to determine optimum platelet doses for many common clinical situations.

Blood Platelet Disorders↗
PubMed2003

Detection and identification of platelet antibodies in clinical disorders.

Serologic assays to detect and identify platelet-reactive antibodies have progressed from less sensitive and specific Phase I tests based on platelet functional endpoints through more sensitive Phase II assays that detect platelet-associated immunoglobulins, to highly specific Phase III assays that detect antibodies bound to alloantigens located on isolated platelet surface glycoproteins. Phase II and III assays are useful in the evaluation of patients with suspected platelet alloimmune syndromes neonatal alloimmune thrombocytopenia (NATP) and post-transfusion purpura (PTP) as well as in platelet crossmatching. Flow cytometry, a Phase II assay, can be modified to detect drug-dependent platelet-reactive antibodies. 14C-serotonin release, a Phase I assay and the platelet factor 4 ELISA, a Phase III assay, are now used to diagnose patients with heparin-induced thrombocytopenia (HIT). A sufficiently sensitive and specific assay to diagnose idiopathic (autoimmune) thrombocytopenia (ITP) remains elusive.

Blood Platelet Disorders↗